Unigene Labs, Inc (UGNE)

Watch the video to learn about the probability of Unigene Labs, Inc (UGNE) Chart Signal as of Apr 19 2014

Hotstocked Precision will calculate the probabilities of Unigene Labs, Inc (UGNE)

Rating:
Size: 656KB
Version: 1.1
Platform: Win/Mac
Downloads:
FREE DOWNLOAD
Recent Material Events for Unigene Labs, Inc
Date Description
Dec 21, 2012 Unigene Laboratories, Inc. (the “Company”) today announced that a settlement agreement was entered into between the Company and Ostrolenk Faber LLP (“Ostrolenk”), the Company’s former patent counsel. ...
Dec 21, 2012 Unigene Laboratories, Inc. (the “Company”) today announced that a settlement agreement was entered into between the Company and Ostrolenk Faber LLP (“Ostrolenk”), the Company’s former patent counsel. ...
Dec 21, 2012 On December 21, 2012, Unigene Laboratories, Inc., a Delaware corporation (the "Company"), entered into an agreement (the "Revised Settlement Agreement") with the Jaynjean Levy Family Limited Partnership (the “Partnership”), Warren P. Levy ...
Dec 21, 2012 On December 21, 2012, Unigene Laboratories, Inc., a Delaware corporation (the "Company"), entered into an agreement (the "Revised Settlement Agreement") with the Jaynjean Levy Family Limited Partnership (the “Partnership”), Warren P. Levy ...
Dec 19, 2012 Unigene Laboratories, Inc. today announced that the Special Meeting of Shareholders in Lieu of the 2012 Annual Shareholder meeting scheduled for January 15, 2013 in Chicago has been postponed until further notice, pending the completion of the financ ...
Dec 14, 2012 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. ...
Dec 12, 2012 On September 8, 2011, the United States Patent and Trademark Office (“USPTO”) granted a request for inter partes reexamination of the Fortical Patent filed by Apotex on July 15, 2011. Unigene filed its response to the Reexamination Office ...
Dec 12, 2012 On December 12, 2012, Unigene Laboratories, Inc. (the “ Company ”) a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that the results of its successful Phase 2 clinical trial evaluating ...
Dec 12, 2012 On September 8, 2011, the United States Patent and Trademark Office (“USPTO”) granted a request for inter partes reexamination of the Fortical Patent filed by Apotex on July 15, 2011. Unigene filed its response to the Reexamination Office ...
Dec 11, 2012 On December 11, 2012, Unigene Laboratories, Inc. (the “ Company ”) announced that it has retained Canaccord Genuity to assist the Company with its exploration and evaluation of a broad range of strategic options, including, but not limite ...